Reading, United Kingdom
Novai, founded in 2020, is a UK-based startup at the vanguard of biotechnology, melding AI with groundbreaking retinal biomarker technology. Their innovation, DARC (Detection of Apoptosing Retinal Cells), seeks to revolutionize early detection and treatment in both ophthalmic and neurodegenerative diseases like macular degeneration, glaucoma, and Alzheimer's.
With the slogan "DARC, a retinal biomarker with AI, advancing drug development for AMD & glaucoma therapeutics," Novai prioritizes early intervention to thwart blindness and disability. The tech stands out as the only solution capable of visualizing individual cell stress and death in the retina, providing indispensable insights for clinical decisions.
Led by a skilled leadership team, Novai possesses robust IP rights and aims at a $40 billion market. It has secured £4.5 million in investments, complemented by £3.3 million in non-dilutive funding, and is eyeing an additional £10 million to mainstream its clinic applications. The startup has already inked £4.2 million in sales contracts—affirming its value proposition to pharmaceutical companies.
Recent engagements include a £850K seed round investment in January 2023 from SFC Capital, marking a strong investor confidence in Novai's potential impact.
